TAM receptors, comprising of Tyro3, Axl and Mertk receptors, are receptor tyrosine kinases (RTKs) that are expressed by multiple immune cells including NK cells.The mature immune, nervous, and reproductive systems depend on the TAM family of receptors and their ligands, Gas6 and Protein S (PROS1), for the best phagocytosis of apoptotic cells.
Three homologous type I receptor-tyrosine kinases known as TAMs are triggered by PROS1 and GAS6, two endogenous ligands. These ligands can either act as soluble factors to activate TAMs or act as connecting molecules between TAMs and apoptotic cells (ACs) by opsonizing phosphatidylserine (PS) on ACs. Cancer cell survival and proliferation as well as the suppression of anti-tumor immunity have been linked to abnormal TAM expression and activation.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V69563 | Anticancer agent 109 | 2097497-16-8 | Anticancer agent 109 (compound 6-15) is an inhibitor (blocker/antagonist) of the Gas6-Axl axis and has tumor suppressor activity. | |
V69487 | AXL-IN-13 | 2376928-82-2 | AXL-IN-13 is a potent, orally bioactive AXL inhibitor (IC50= 1.6 nM, Kd: 0.26 nM). | |
V69569 | AXL-IN-14 | 2947506-65-0 | AXL-IN-14 is a potent orally bioactive AXL inhibitor (antagonist) with IC50 of 0.8 nM. | |
V69571 | AXL-IN-15 | 1954722-22-5 | AXL-IN-15 (cpd391) is a potent Axl inhibitor (antagonist) with Ki and IC50 <1 nM. | |
V84743 | Axl-IN-17 | |||
V69572 | Axl-IN-3 | 2783991-34-2 | Axl-IN-3 is a specific, orally bioactive AXL kinase inhibitor (antagonist) with IC50 of 41.5 nM. | |
V69282 | Axl/Mer/CSF1R-IN-1 | 2394874-60-1 | Axl/Mer-IN-1 (Compound 1) is an inhibitor (blocker/antagonist) of Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R with Kds less than 0.1 μM. | |
V69280 | Axl/Mer/CSF1R-IN-2 | 2394874-63-4 | Axl/Mer/CSF1R-IN-2 (Comp 4) is an inhibitor (blocker/antagonist) of Axl, Mer and CSF1R. | |
V69570 | AZ14145845 | 2830555-70-7 | AZ14145845 is a selective Mer/Axl type I1/2 dual-specific kinase inhibitor (antagonist) with in vivo efficacy. | |
V69565 | Batiraxcept (AVB-S6-500) | 2268717-61-7 | Batiraxcept (AVB-S6-500) is a potent and specific AXL inhibitor that is a recombinant fusion protein dimer containing the extracellular domain of human AXL and the human immunoglobulin G1 heavy chain (Fc). | |
V88082 | BPR5K230 | 3029897-97-7 | BPR5K230 is a dual inhibitor of receptor tyrosine kinases MER and AXL with IC50 of 4.1 nM and 9.2 nM, respectively. | |
V91785 | ER-851 | 2685738-33-2 | ER-851 is an orally active, selective AXL inhibitor with IC50 of 100 nM. | |
V0638 | LDC1267 | 1361030-48-9 | LDC1267 (LDC-1267) is a novel, highly potent and selective TAM (Tyro3, Axl and Mer) kinase inhibitor with potential antitumor activity. | |
V0595 | NPS-1034 | 1221713-92-3 | NPS-1034 (NPS1034; NPS 1034) is a novel, potent dual inhibitor of the tyrosine kinases Met and Axl with potential antineoplastic activity. | |
V3425 | SGI-7079 | 1239875-86-5 | SGI-7079 (SGI7079) is a novel, potent and selective Axl inhibitor with potential anti-inflammatory and anticancer activities. | |
V0636 | UNC2250 | 1493694-70-4 | UNC2250 (UNC-2250) is a novel, potent and selective Mer inhibitor with potential antitumor activity. | |
V0637 | UNC2881 | 1493764-08-1 | UNC2881 (UNC-2881) is a novel, potent and specific Mer tyrosine kinase inhibitor with potential utility for prevention and treatment of pathologic thrombosis. | |
V69566 | UNC1062 | 1350549-36-8 | UNC1062 is a MERTK-selective tyrosine kinase inhibitor that reduces the activation of MERTK-mediated downstream signaling, causes apoptosis in culture, reduces colony formation in soft agar, and inhibits melanoma cell invasion. | |
V69248 | UNC5293 | 2226789-82-6 | UNC5293 is a selective inhibitor of MERTK (Ki=190 pM). | |
V5018 | UNC569 | 1350547-65-7 | UNC569 is a novel, potent and selective small-molecule MER inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. |